by Sue Robbins | Dec 30, 2019 | Migraine
Patients who visit urgent care centers for acute migraine often do not receive the emergency treatment as recommended according to guidelines from the American Headache Society (AHS), according to study results published in Headache. Urgent care centers are emerging...
by Sue Robbins | Dec 26, 2019 | Migraine
The FDA has approved ubrogepant (Ubrelvy; Allergan) for the acute treatment of migraine with or without aura in adults, making it the first-in-class oral calcitonin gene-related peptide (CGRP) antagonist for this indication.1 The new drug application (NDA) was...
by Sue Robbins | Dec 23, 2019 | Migraine
Aura has long been a perplexing issue in migraine. Primarily viewed as a prodromal sign of migraine in some patients some of the time, aura has been largely overlooked in clinical trials that tend to enroll patients with migraine with and without aura.1 However, new...
by Sue Robbins | Dec 19, 2019 | Migraine
Nearly half of all patients who suffer migraines report sleep disturbance as a trigger for their headaches. But the relationship between sleep and migraine headaches is not well understood or well-studied. Investigators from Brigham and Women’s Hospital and Beth...
by Sue Robbins | Dec 18, 2019 | Migraine
A study in the Journal of the American Medical Association indicates that ubrogepant demonstrated greater rates of pain and symptom relief from migraine compared with a placebo. More than 20% of participants in a large-scale clinical trial reported being pain-free...
